Baselaunch alumnus T3 Pharma acquired by Boehringer Ingelheim
T3 Pharma, which uses live bacteria to deliver immune-modulating proteins to cancer cells, has been acquired for up to 450M Swiss francs.
More details on the BaseLaunch website.
T3 Pharma, which uses live bacteria to deliver immune-modulating proteins to cancer cells, has been acquired for up to 450M Swiss francs.
More details on the BaseLaunch website.
Double builds companies. Occasionally on our own, more usually with others. Sometimes part of the founding team, sometimes working with established companies to help get things moving.